Heparan sulfate proteoglycan is an important attachment factor for cell entry of Akabane and Schmallenberg viruses by Murakami, Shin et al.
 
 
 
 
 
Murakami, S., Takenaka-Uema, A., Kobayashi, T., Kato, K., Shimojima, 
M., Palmarini, M.  and Horimoto, T. (2017) Heparan sulfate proteoglycan is 
an important attachment factor for cell entry of Akabane and Schmallenberg 
viruses. Journal of Virology, 91(15), e00503-17.     
(doi:10.1128/JVI.00503-17)  
This is the author’s final accepted version. 
 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it. 
 
http://eprints.gla.ac.uk/141940/                                                                                                                         
 
 
 
 
 
 
Deposited on: 03 July 2017 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk  
1 
 
Heparan sulfate proteoglycan is an important attachment factor for cell 1 
entry of Akabane and Schmallenberg viruses 2 
 3 
 4 
Shin Murakamia,#, Akiko Takenaka-Uemab, Tomoya Kobayashia, Kentaro Katoa,c, 5 
Masayuki Shimojimaa,d, Massimo Palmarinie, and Taisuke Horimotoa,# 6 
 7 
Department of Veterinary Microbiology, Graduate School of Agricultural and Life 8 
Sciences, The University of Tokyo, Tokyo, Japana; 9 
Department of Infection Control and Disease Prevention, Graduate School of 10 
Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japanb; 11 
National Research Center for Protozoan Diseases, Obihiro University of 12 
Agriculture and Veterinary Medicine, Obihiro, Japanc; 13 
Department of Virology I, Special Pathogens Laboratory, National Institute of 14 
Infectious Diseases, Tokyo, Japand; 15 
MRC-University of Glasgow Centre for Virus Research, Glasgow, United 16 
Kingdome 17 
 18 
Running Head: HSPG is an attachment factor for AKAV and SBV entry 19 
 20 
# Address correspondence to Shin Murakami, 21 
amurakam@mail.ecc.u-tokyo.ac.jp and Taisuke Horimoto, 22 
ahorimo@mail.ecc.u-tokyo.ac.jp 23 
 24 
Word count  25 
Abstract 141 words 26 
Text 3,709 words 27 
 28 
 29 
 30 
 31 
 32 
 33 
 34 
 35 
 36 
2 
 
Abstract 37 
Akabane (AKAV) and Schmallenberg (SBV) viruses are Orthobunyavirus 38 
transmitted by arthropod vectors with a broad cellular tropism in vitro as well as 39 
in vivo. Both AKAV and SBV cause arthrogryposis-hydranencephaly syndrome 40 
in ruminants. The main cellular receptor and attachment factor for entry of these 41 
orthobunyaviruses are unknown. Here, we found that AKAV and SBV infections 42 
were inhibited by the addition of heparin or enzymatic removal of cell surface 43 
heparan sulfates. To confirm this finding, we prepared heparan sulfate 44 
proteoglycan (HSPG)-knockout (KO) cells by using a CRISPR/Cas9 system and 45 
measured the binding quantities of these viruses to cell surfaces. We observed a 46 
substantial reduction in AKAV and SBV binding to cells, limiting the infections by 47 
these viruses. These data demonstrate that HSPGs are important cellular 48 
attachment factors for AKAV and SBV, at least in vitro, to promote virus 49 
replication in susceptive cells.  50 
 51 
Importance 52 
AKAV and SBV are the etiological agents of arthrogryposis-hydranencephaly 53 
syndrome in ruminants, which causes considerable economic losses in the 54 
livestock industry. Here, we identified heparan sulfate proteoglycan as a major 55 
cellular attachment factor for the entry of AKAV and SBV. Moreover, we found 56 
that heparin is a strong inhibitor of AKAV and SBV infections. Revealing the 57 
molecular mechanisms of virus-host interactions is critical in order to understand 58 
virus biology and develop novel live attenuated vaccines.  59 
 60 
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Introduction 61 
 The Akabane (AKAV) and Schmallenberg (SBV) viruses belong to the 62 
Simbu serogroup of the arthropod-borne Orthobunyavirus genus of the family 63 
Bunyaviridae. AKAV and SBV are phylogenetically closely related and they also 64 
possess similar biological characteristics: (i) both cause abortion, stillbirth, 65 
premature birth, and congenital deformities in cattle, sheep, and goats; (ii) both 66 
primarily infect the central nervous system (CNS) of the fetus; (iii) both are 67 
difficult to control, because they are transmitted by biting midges of the genus 68 
Culicoides (1). Both AKAV and SBV cause “abortion storms” that result in 69 
considerable economic losses to the livestock industry (2-4).  70 
Despite these similarities, there are important features that distinguish 71 
these two viruses. AKAV is endemic throughout Australia, Southeast Asia, East 72 
Asia, the Middle East, and Africa, whereas SBV has emerged and has dispersed 73 
across a large area of Europe since 2011. AKAV comprises four genogroups (I–74 
IV), whereas SBV comprises a single genotype. No differences in the 75 
pathogenicity of different SBV strains have been described. On the other hand, 76 
the OBE-1 strain of AKAV [AKAV(OBE-1)] (genogroup I) causes severe fetal 77 
malformation, whereas the Iriki strain [AKAV(Iriki)] (genogroup II) causes also 78 
fatal non-suppurative encephalomyelitis in newborn cattle. Molecular 79 
determinants distinguishing the pathogenicity of these two different strains are 80 
unknown (5).  81 
 Orthobunyaviruses carry a tripartite, single-stranded, negative-sense 82 
RNA genome. The L segment encodes the L protein, a viral RNA-dependent 83 
RNA polymerase; the S segment encodes the N protein and the non-structural 84 
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protein NSs, both transcribed from an overlapping open reading frame; and the 85 
M segment encodes NSm, and the two major viral envelope proteins, Gn and Gc 86 
(Gn/Gc), which form heterodimeric spikes on the virus particle. Gn/Gc are the 87 
proteins on the surface of the virion that bind to cell surface molecules in the 88 
initial step of orthobunyavirus infection (6, 7). Relatively few studies have 89 
investigated orthobunyavirus entry. La Crosse and Germiston neurotropic 90 
orthobunyavirus entry into the cell has been described to be promoted by 91 
DC-SIGN (8, 9). However, DC-SIGN is probably not the main attachment factor 92 
of ruminant orthobunyaviruses, because it is expressed on macrophages and 93 
dendritic cells, not in the CNS. Heparan sulfate proteoglycan (HSPG), one of 94 
major negatively charged transmembrane protein-linking glycosaminoglycans, is 95 
expressed by almost all cells, including neural cells. HSPG is involved in cell 96 
attachment of many viruses [e.g., herpes simplex virus (10, 11), adenovirus (12) 97 
respiratory syncytial virus (13, 14), human papilloma virus (15), foot-and-mouth 98 
disease virus (16), hepatitis B virus (17), hepatitis C virus (18), Ebola virus (19, 99 
20), dengue virus (21), and human immunodeficiency virus (22)]. In addition, 100 
HSPG is involved in cell attachment of phleboviruses in the family Bunyaviridae, 101 
including Rift Valley fever virus and Toscana virus (23-25). In a previous report, 102 
hemagglutination of AKAV was inhibited by the addition of heparin, a form of 103 
heparan sulfate (26). Therefore, it is possible that HSPGs are involved in AKAV 104 
and/or SBV infection, similarly to other viruses.  105 
 In this study we examined the role of HSPGs in AKAV and SBV 106 
replication.  107 
 108 
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Materials and Methods 109 
Cells. Baby hamster kidney cells stably expressing T7 RNA polymerase 110 
(BHK/T7-9 cells) (27) were kindly provided by Dr. Naoto Ito (Gifu University, 111 
Japan) and cultured in Dulbecco's modified Eagle's minimum medium (DMEM) 112 
supplemented with 5% fetal calf serum (FCS) and 10% tryptose phosphate broth 113 
at 37°C. Golden hamster lung (HmLu-1) cells were cultured at 37°C in DMEM 114 
supplemented with 5% FCS. Human embryonic kidney (HEK293T) cells were 115 
maintained in DMEM supplemented with 10% FCS.  116 
 117 
Viruses. AKAV OBE-1 and Iriki strains (28, 29) and SBV (30) were generated by 118 
reverse genetics. Briefly, to recover AKAV(Iriki), 1.2 μg of pT7riboSM2/IL, 0.6 μg 119 
of pT7riboSM2/IM, and 1.2 μg pT7riboSM2/IS plasmids were mixed in 200 μL of 120 
Opti-MEM (GIBCO, Grand Island, NY, USA) with 9 μL of Trans-IT LT1 (Mirus Bio, 121 
Madison, WI, USA) transfection reagent, incubated at room temperature for 15 122 
min and then added to BHK-T7 cells (27) grown in 6-well plates. To recover 123 
AKAV(OBE-1), 1.2 μg of pT7riboSM2/OL, 0.6 μg of pT7riboSM2/OM, and 1.2 μg 124 
of pT7riboSM2/OS plasmids were transfected into BHK-T7 cells, as described 125 
for AKAV(Iriki) generation. To recover SBV, 1 µg of each pUCSBVST7, 126 
pUCSBVMT7, and pUCSBVLT7 plasmids and 2 μg of a plasmid expressing T7 127 
polymerase under control of the chicken β-actin promoter (pCAGGS-T7pol) 128 
were mixed in 300 μL of Opti-MEM (GIBCO) with 15 μL of Trans-IT 293 (Mirus) 129 
transfection reagent, incubated at room temperature for 15 min, and then added 130 
to HEK293T cells grown in 6-well plates. At 3 days post-transfection, the culture 131 
supernatant of transfected cells was harvested and added to HmLu-1 cells. 132 
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Viruses were propagated in HmLu-1 cells cultured in DMEM supplemented with 133 
2% FCS. Non-spreading vesicular stomatitis virus (VSV-ΔG-GFP) pseudotyped 134 
with its own glycoprotein G was propagated following transfection of the VSV G 135 
protein-expressing plasmid (pCAGGS-VSVG) into HEK293T cells (31). 136 
VSV-pseudotyped virus with AKAV Gn and mutant Gc was also propagated in 137 
HEK293T cells following transfection of the mutant Gn/Gc/NSm of AKAV(OBE-1), 138 
which lacks a 10-amino-acid region in the C-terminal of the wildtype Gc. This 139 
mutant was made since VSV-pseudotyped virus with Gn and mutant Gc lacking 140 
C-terminal of cytoplasmic-tail glycoproteins of Crimian-Congo hemorrhagic fever 141 
(CCHF) virus, a member of Bunyaviridae, showed higher titer than 142 
VSV-pseudotyped virus with wild-type CCHF Gn/Gc proteins (32).  143 
 144 
Production of polyclonal antibodies to AKAV or SBV. An anti-AKAV mouse 145 
polyclonal antibody (pAb) was prepared by two intraperitoneal injections of 146 
sucrose gradient-purified AKAV(OBE-1) into 6-week-old female ICR mice (Japan 147 
SLC, Hamamatsu, Japan) at 2-week intervals. An anti-SBV mouse polyclonal 148 
antibody (pAb) was prepared by two intraperitoneal injections of sucrose 149 
gradient-purified SBV in 6-week-old female ICR mice (Japan SLC) at 2-week 150 
intervals. Reactivities and specificities of both anti-SBV and anti-AKAV pAbs 151 
were confirmed by immunofluorescent assay, using AKAV(OBE-1)- or 152 
SBV-infected and mock-infected HmLu-1 cells. 153 
 154 
Plaque assay. A standard plaque assay was used to determine the infectivity of 155 
AKAV and SBV. After virus adsorption to HmLu-1 cells for 1 h at 37°C, the 156 
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inocula were removed, and cells were overlaid with DMEM containing 0.6% 157 
agarose and 2% FCS. After incubation for 3 days, cells were stained with neutral 158 
red before counting plaque-forming units (PFUs). 159 
 160 
Plaque reduction assay. One hundred microliters of serial two-fold dilutions of 161 
heparin solution were prepared in MEM containing 0.3% bovine serum albumin 162 
(BSA/MEM). An equal volume of the suspensions containing 100 PFU/100 µL of 163 
AKAV(OBE-1), AKAV(Iriki), or SBV were added to each dilution. After incubation 164 
for 30 min at room temperature (RT), 200 µL of each virus-heparin mixture 165 
(containing 100 PFU of viruses) was titrated by the plaque assay. 166 
  167 
Heparinase treatment. Cells were seeded in 48-well plates 24h prior to 168 
infection. Medium was removed, and the cells were incubated with serial 169 
four-fold dilutions of heparinase II (New England Biolabs) in BSA/MEM with 2 170 
mM CaCl2 for 1 h at 37°C and then washed with BSA/MEM. The plates were 171 
immediately transferred on ice to suppress the synthesis and transport of HSPG. 172 
We then added the appropriate amounts of AKAV(OBE-1), AKAV(Iriki), or SBV to 173 
100 µL of BSA/MEM and incubated the mixture for 1 h on ice. Supernatant was 174 
removed and cells washed twice with BSA/MEM, and DMEM with 5% FCS 175 
before incubation for 8 h at 37°C. The cells were then fixed with 4% 176 
paraformaldehyde for 15 min at RT. After removing paraformaldehyde, the cells 177 
were permeabilized with 0.1% Triton-X 100 and incubated with anti-AKAV N 178 
mouse monoclonal antibody (mAb) (5E8) (33) for AKAV-infected cells or 179 
anti-SBV mouse polyclonal antibody pAb for SBV-infected cells, followed by 180 
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incubation with Alexa Fluor 488-conjugated anti-mouse IgG antibody. The 181 
fluorescence-positive cells were counted as AKAV- or SBV-infected cells under 182 
fluorescent microscopy (Vert. A1, Carl Zeiss). 183 
 184 
EXT2-KO cells. EXT2-KO cells were established using the CRISPR/Cas9 185 
system. EXT2 gene target sequences (EXT2-1: CTATCCCCTGAAAAAGTACG 186 
or EXT2-2: CTACACGGATGACATCAGCC) containing oligos were introduced 187 
into the guide RNA (gRNA) expression cassette of the plentiCRISPR vector (a 188 
gift from Dr. Feng Zhang, Addgene plasmid #52961) (34). A random target 189 
sequence (N20) containing oligos was also introduced into the gRNA expression 190 
cassette of the plentiCRISPR vector. One µg of the plentiCRISPR plasmid 191 
containing each target gRNA sequence was transfected into HmLu-1 cells (1 × 192 
105 cells) with TransIT-LT1 (Mirus). One day after transfection, media were 193 
replaced with 10 μg/mL of puromycin-containing media for 5 days of selection. 194 
Surviving cells were passaged, diluted, and inoculated onto fresh dishes for 195 
colony formation. Each colony was picked, propagated, and genotyped. The 196 
genomic region surrounding the CRISPR/Cas9 target site for each gene in 197 
cloned cell was PCR-amplified with KOD-FX neo (TOYOBO), and the PCR 198 
products were gel extracted and sequenced using a 3130 Genetic Analyzer 199 
(ABI). Primer sequences are available upon request. Clones with indels 200 
introduced at the targeted site were picked. Genotyped clones were detached 201 
with phosphate-buffered saline (PBS) containing ethylenediaminetetraacetic 202 
acid (EDTA) and incubated with anti-heparan sulfate mAb (10E4) (USBio) (35) 203 
followed by incubation with Alexa Fluor 488-conjugated anti-mouse IgM antibody 204 
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(AbCam). IgM clone MOPC 104E (Sigma, St. Louis, MO, USA) was used as an 205 
isotype control. Labeled cells were analyzed by flow cytometry (FACSVerse, BD 206 
Biosciences).  207 
 208 
Real-time reverse transcription-polymerase chain reaction (RT-PCR) for 209 
the quantification of cell surface-attached viruses. For virus absorption on 210 
cells, 1 x 107 PFU/mL of AKAV(OBE-1), AKAV(Iriki), or SBV were inoculated onto 211 
HSPG-KO or random-KO HmLu-1 cells for 1 h at 4 °C. After 1 h of incubation, 212 
unbound viruses were washed three times with ice-cold BSA/MEM. Virus-bound 213 
cells were lysed, and the total RNA was extracted with ISOGEN (Nippon Gene). 214 
The extracted RNAs were assayed using RNA-direct SYBR Green Real-time 215 
PCR Master Mix (Toyobo), according to the manufacturer's instructions, in a 216 
Thermal Cycler Dice Real Time System (Takara). One µg of the extracted RNAs 217 
were amplified using the AKAV S RNA-specific primer set (forward 5′218 
-CCACAACCAAGTGTCGATCT-3′; reverse 5′-AGATGCGGTGAAGCGTAAA-3′), 219 
or SBV S RNA-specific primer set (forward 220 
5′-GGCCAAGATGGTCCTACATAAG-3′; reverse 221 
5′-TGTCTGGCACAGGATTTGAG-3′). The RNA was normalized to host GAPDH 222 
mRNA using a golden hamster GAPDH-specific primer set (forward 223 
5′-AAGGTCATCCCAGAGCTGAA-3′; reverse 224 
5′-CTGCTTCACCACCTTCTTGA-3′). For relative quantification, a standard 225 
curve of AKAV or SBV S RNA and GAPDH was prepared by serial dilution of the 226 
mixture of total RNA extracted from uninfected HmLu-1 cells and viral RNA 227 
extracted from AKAV(OBE-1)- or SBV-containing supernatants.  228 
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 229 
Sandwich ELISA for the detection of N proteins of cell surface-attached 230 
AKAV. For virus absorption on cells, 1 x 107 PFU of AKAV(OBE-1) was 231 
inoculated onto HSPG-KO or control HmLu-1 cells in 6-well plates for 1h at 4°C. 232 
After 1 h of incubation, unbound viruses were washed three times with ice-cold 233 
BSA/MEM. Then, virus-bound cells were lysed with lysis buffer containing 10 234 
mM Tris-HCl (pH 7.4), 0.5% TritonX-100, 150 mM NaCl, and 1 mM EDTA for 10 235 
min on ice. The lysates were collected and clarified by centrifugation (10,000 x g 236 
for 5 min at 4 °C). Supernatants were then added to the anti-AKAV N mAb 237 
(5E8)-coated wells of 96-well ELISA plates (Maxisorp, Nunc) and incubated for 238 
30 min at RT. After washing with PBS-0.1% Tween 20 (PBS-T), biotinylated 239 
(Biotin Labeling Kit-NH2, Dojindo) anti-AKAV mouse pAb was added to the wells 240 
and incubated for 30 min at RT. After washing with PBS-T, avidin-biotinylated 241 
horseradish peroxidase (HRP) complex (VECTASTAIN ABC Kit, Vector 242 
Laboratories) was added to the wells and incubated for 30 min at RT. A 243 
3,3′,5,5′-tetramethylbenzidine (TMB) substrate solution was used to read the 244 
assay. 245 
 246 
EXT2 gene reintroduction into HSPG-KO cells. The golden hamster EXT2 247 
open reading frame sequence (GenBank accession number XM_013118841) 248 
was amplified from a pool of cDNA, which was a product of reverse transcription 249 
of total RNA from HmLu-1 cells, using an EXT2-specific primer set. A pS 250 
lentivirus transfer vector under the control of the spleen focus-forming virus 251 
promoter was prepared by removing the Venus gene from pSVenusfull vector 252 
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(36) by BamHI and NotI digestion. Amplified EXT2 cDNA was cloned into the pS 253 
lentivirus vector and designated as pS-EXT2. The lentivirus EXT2-expression 254 
vector was produced in HEK293T cells by co-transfection of the transfer vector 255 
pS-EXT2 and two lentivirus packaging plasmids p8.9QV (37) and 256 
pCAGGS-VSVG. The lentivirus vector was concentrated by ultracentrifugation 257 
and inoculated onto EXT2-KO HmLu-1 cells. HSPG expression was confirmed 258 
by flow cytometry as described above. 259 
 260 
Statistical analysis. All samples were compared by Student’s t-test with 261 
two-tailed analysis to determine statistically significant differences. 262 
 263 
Results 264 
Heparin or heparinase treatment inhibits AKAV and SBV infections. 265 
Heparin is a highly sulfated form of heparan sulfate (38) and is a known inhibitor 266 
of infection by various viruses. To test whether heparin inhibits AKAV or SBV 267 
replication, AKAV and SBV were incubated with different concentrations of 268 
heparin for 30 min and the titers of the viruses neutralized by heparin were 269 
measured by plaque reduction assay in HmLu-1 cells (Fig. 1A), which support 270 
efficient replication of the Akabane and Schmallenberg viruses and abundantly 271 
express heparan sulfate. The number of plaques induced by either AKAV or SBV 272 
was reduced in a heparin concentration-dependent manner. These data suggest 273 
that heparin affects the replication cycle of both viruses.  274 
Next, we pre-treated HmLu-1 cells with heparinase to remove HPSG from 275 
the cell surface and subsequently infected them with AKAV(OBE-1), AKAV(Iriki), 276 
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SBV. We also used or VSV-ΔG-GFP, a VSV-based vector expressing GFP that 277 
can complete only a single replication cycle within the cell (31), because this 278 
virus does not utilize HSPG during the early events of infection (23, 39). At 8 h 279 
post-infection (hpi), cells were fixed and stained with anti-AKAV or anti-SBV 280 
antibodies for the detection of AKAV- or SBV-infected cells, respectively. 281 
GFP-positive cells were instead counted to determine the number of 282 
VSV-ΔG-GFP-infected cells. As shown in Fig. 1B, VSV-ΔG-GFP was not 283 
susceptible to heparinase treatment, whereas the number of cells infected by 284 
AKAV and SBV were reduced in a heparinase concentration-dependent manner. 285 
SBV was more susceptible to heparinase treatment than the AKAVs (p<0.05 at 286 
20 and 78 µU/µL of heparinase). These data suggest that HSPG plays important 287 
roles in AKAV and SBV infections.  288 
 289 
AKAV and SBV replication in HSPG-KO cells. In order to further validate the 290 
data shown above, we established HSPG-KO cells using a CRISPR/Cas9 291 
system (34) disrupting the EXT2 gene, which encodes one of the 292 
HSPG-synthesizing enzymes (38). We designed two gRNAs (EXT2-1 and 293 
EXT2-2) targeting different positions in the EXT2 gene and obtained three 294 
clones for each target (EXT2KO-1-1, -1-2, -1-3, -2-1, -2-2, and -2-3 cells). We 295 
also established control “random-KO” HmLu-1 cells by introducing a 20-nt 296 
random target sequence in the gRNA with the CRISPR/Cas9 system and 297 
obtained three clones of the random-KO cells (Random-KO-1, -2, and -3). Lack 298 
of HSPG expression in HSPG-KO cells, but not in random-KO or wild type cells, 299 
was confirmed by flow cytometry analysis (Fig 2A). In the HSPG-KO cells, titers 300 
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of AKAV(OBE-1) and AKAV(Iriki) were about 100 fold lower than that in 301 
random-KO cells at 24 hpi but were of similar levels at later time points (Fig. 2B). 302 
SBV titers were instead between 10 to 1000 fold lower in HSPG-KO cells than in 303 
random-KO cells throughout the course of the experiment (Fig. 2B). Next, we 304 
examined AKAV and SBV infectivity in the EXT2-KO cells and random-KO cells. 305 
EXT2-KO cells or random-KO cells were infected with AKAV(OBE-1), AKAV(Iriki), 306 
SBV or VSV-ΔG-GFP (moi of 0.1). At 8 hpi, AKAV, SBV antigen-positive cells or 307 
GFP-positive cells were counted (Fig 2C). Control VSV-ΔG-GFP-infected cell 308 
numbers were not significantly different between random-KO and HSPG-KO 309 
cells. Five to ten times lower numbers of AKAV and SBV antigen-positive cells 310 
were detected in EXT2-KO cells compared to those in random-KO cells. To 311 
eliminate the possibility that replication step of AKAV affected the results shown 312 
in Fig. 2C, we used a VSV-pseudotyped virus bearing AKAV glycoproteins 313 
(VSV-ΔG-GFP/AKAV). VSV-ΔG-GFP/AKAV or VSV-ΔG-GFP was inoculated into 314 
EXT2-KO cells or random-KO cells. At 8 hpi, GFP-positive cells were counted 315 
(Fig. 2D). As shown in Fig. 2C, control VSV-ΔG-GFP-infected cell numbers did 316 
not show significant difference between random-KO and HSPG-KO cells. 317 
However, GFP-cells detected were three times less in EXT2-KO cells than in 318 
random-KO cells (p<0.01). These data indicated that HSPG was important for 319 
AKAV and SBV infections. 320 
 321 
Quantification of AKAV and SBV bound to HSPG-KO cells surface. To 322 
determine whether HSPG is important for AKAV and SBV cell surface 323 
attachment, we quantified the amounts of cell surface-bound viruses. 324 
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AKAV(OBE-1) and SBV were incubated with EXT2-KO-1, EXT2-KO-2, or 325 
random-KO cells for 1h at 4°C and virus-bound cells were collected. RNA was 326 
extracted from the cells and AKAV or SBV RNA (S segment) was quantified by 327 
qRT-PCR (Fig. 3A). AKAV and SBV RNA was significantly lower in HSPG-KO 328 
cells than in random-KO cells (p<0.01). We also measured cell-bound AKAV by 329 
quantifying N protein using an N-detecting sandwich ELISA (Fig. 3B). Cell 330 
surface bound N proteins were significantly lower in EXT2-KO-1 and EXT2-KO-2 331 
cells than in random-KO cells, confirming the qRT-PCR results. These data 332 
suggest that HSPG is an important molecule for AKAV and SBV cell surface 333 
attachment. 334 
 335 
AKAV and SBV replication is restored in EXT2 add-back cells. We next 336 
transduced the EXT2-KO cells with the EXT2 gene, in order to confirm that 337 
AKAV and SBV replication could be restored by simply reintroducing the EXT2 338 
gene back to EXT2-KO cells. We first confirmed that HSPG expression was 339 
restored in these cells by flow cytometry (Fig. 4A). Next, we examined AKAV and 340 
SBV infectivity in the EXT2 gene transduced EXT2-KO cells and wild-type cells. 341 
EXT2-KO cells or wild-type cells were infected with AKAV(OBE-1), AKAV(Iriki),or 342 
SBV. At 8 hpi, AKAV-, SBV-infected cells were detected (Fig 4B). As expected, 343 
infectivity of AKAV(OBE-1), AKAV(Iriki), and SBV was restored in the EXT2 344 
add-back cells. 345 
346 
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Discussion 347 
 AKAV and SBV infect neurons (2, 4, 30) and a broad range of cells in the 348 
infected hosts. This suggests that AKAV and SBV use cellular receptor(s) or 349 
attachment factor(s) that are expressed on a variety of cells. DC-SIGN was 350 
previously shown to promote La Crosse and Germiston neurotropic 351 
orthobunyavirus entry (8, 9). However, the distribution of DC-SIGN is not 352 
consistent with the tropisms of either AKAV or SBV, because DC-SIGN is 353 
expressed on a limited number of cell types (i.e., dendritic cells and 354 
macrophages). Here, we demonstrated that HSPG plays an important role in 355 
AKAV and SBV infections as an attachment factor. Cell surface HSPGs are 356 
expressed ubiquitously throughout the body (38), including on neuronal cells 357 
(40). Therefore, our data support the correlation between HSPG distribution and 358 
AKAV and SBV tropism. However, AKAV and SBV show a strong preference for 359 
neuronal cells in vivo and there are likely other reasons for this. AKAV and SBV 360 
were still able to replicate in HSPG-KO cells, although at lower levels than to 361 
those in HSPG-expressing cells. These data suggest the presence of other 362 
cellular factors(s) that defines the tissue tropisms of AKAV and SBV. Further 363 
studies are needed to identify the neuronal cell-specific receptors or reveal other 364 
defining steps after cell entry.  365 
In AKAV (Iriki)-infected HSPG-KO cells, after the virus titer reached a 366 
plateau at 24 and 36 hpi, a second AKAV (Iriki) growth wave was observed at 48 367 
hpi (Fig. 2B). During the AKAV (Iriki) replication in HSPG-KO cells, the virus may 368 
have acquired mutation(s) in the receptor-binding site of the glycoproteins, 369 
possibly leading to adaptation to HSPG-KO cells. Thus, to investigate whether 370 
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the AKAV (Iriki), recovered from HSPG-KO cells at a later time-point of infection, 371 
included mutations in their glycoproteins, we sequenced the entire M segment at 372 
60 hpi but found no mutations. Hence, the mechanism of the second growth 373 
wave of AKAV (Iriki) still remains unknown. Continuous virus passage in 374 
HSPG-KO cells may result in mutations to adapt to other cellular attachment 375 
factor(s) or receptor(s).  376 
 Repetitive passage of some viruses in tissue culture induces one to two 377 
amino acid mutations in their glycoproteins, which increases their affinity toward 378 
HSPGs (41-46). This adaptation also induces viral attenuation in vivo (41-46). A 379 
previous study showed that cell culture-derived SBV showed slightly slowed 380 
replication in cattle; however, the involvement of HSPG underlying this is 381 
unknown (47). Rift Valley fever virus (23), dengue virus (48), and human 382 
t-lymphotropic virus 1 (HTLV-1) (49) do not acquire any mutations after passage 383 
in cell culture, which enhances their affinity toward HSPGs. This suggests that 384 
the species of the virus determines whether the virus adapts to cell culture and 385 
uses HSPGs for entry. AKAV (OBE-1), AKAV (Iriki), and SBV used in the present 386 
study were passaged several times in tissue culture before cloning them into 387 
reverse genetics plasmids. However, AKAV (Iriki) which used in this study 388 
maintained its pathogenic potential against goat fetus and mice (29, 50), 389 
implying that it did not undergo changes during passage in the cell culture. 390 
However, it is unclear whether serial passages in cell culture induced mutations 391 
in Gn/Gc proteins of AKAV and SBV to have higher affinity to HSPG. Therefore, 392 
further studies are needed to compare the HSPG-binding affinity of viral strains 393 
examined with our lab strains and isolates from clinical specimens which have 394 
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original sequences.  395 
 In this study, we showed that the heparinase susceptibly of SBV was 396 
greater than that of AKAVs. In addition, SBV replication in HSPG-KO cells was 397 
limited compared to that of AKAVs. Moreover, AKAV(OBE-1) exhibited slightly 398 
lower HSPG dependency than AKAV(Iriki) did for virus infection and growth. One 399 
possible explanation for the difference in HSPG dependency is that 400 
AKAV(OBE-1), AKAV(Iriki), and SBV possess different sequences in their 401 
HSPG-binding domains and probably in Gn or Gc. Although HSPG-binding 402 
domains have been identified in other viral glycoproteins as well as in cellular 403 
proteins (51), we could not find known HSPG-binding motifs in AKAV and SBV 404 
glycoprotein sequences (data not shown). HSPG-binding domains are not 405 
simply defined by the secondary sequences of HS-binding proteins (51). The 406 
tertiary structure of these proteins and heparan sulfate interactions are also 407 
important for binding. Determining the three-dimensional (3D) structure of Gn/Gc 408 
proteins is likely required to define the binding site more precisely. Although the 409 
orthobunyavirus Gn/Gc 3D structure is not available currently, determining the 410 
3D structure of Gn/Gc proteins is likely required to define the HSPG binding site.  411 
 Here, we clearly show that AKAV and SBV utilize HSPG for their initial 412 
cell surface attachment in gene-edited HSPG-KO cells. These findings further 413 
our understanding of the orthobunyavirus life cycle. Molecules inhibiting 414 
orthobunyavirus and HSPG interactions may be effective antivirals.  415 
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Figure legends 592 
Fig. 1. Effects of heparin and heparinase treatment on AKAV and SBV infections. 593 
(A) Effects of heparin on AKAV and SBV plaque reduction. Various 594 
concentrations of heparin were incubated for 30 min at room temperature with 595 
100 plaque-forming units of AKAV(OBE-1), AKAV(Iriki), or SBV, and the ability of 596 
heparin to reduce plaque formation was assessed. (B) Effects of heparinase 597 
treatment on AKAV and SBV infectivity. HmLu-1 cells were treated with various 598 
concentrations of heparinase II, followed by AKAV or SBV infection. Cells were 599 
stained for AKAV or SBV antigen, and positive cells were counted under a 600 
fluorescent microscope. For VSV-ΔG-GFP-infected cells, GFP-positive cells 601 
were counted under a fluorescent microscope. Results are expressed in 602 
percentages relative to cells that were not treated with heparinase. The data are 603 
reported as the mean value with standard deviations for three independent 604 
experiments. 605 
 606 
Fig. 2. AKAV and SBV growth kinetics and infectivity in HSPG-KO HmLu-1 cells. 607 
(A) Flow cytometric analysis of EXT2-KO HmLu-1 cells. CRISPR/Cas9-mediated 608 
EXT2-KO cell clones (EXT2-1 and EXT2-2) were labeled with anti-heparan 609 
sulfate mouse-monoclonal antibody (10E4) (black) or with isotype control (red) 610 
and analyzed by flow cytometry (FACS verse, BD Biosciences). The 611 
representative data (one out of three clones of random-KO, EXT2KO-1, and 612 
EXT2KO-2) are shown. (B) Growth kinetics of AKAV or SBV in HSPG-KO cells. 613 
AKAV(OBE-1), AKAV(Iriki), or SBV was inoculated onto three clones of 614 
random-KO, EXT2KO-1, and EXT2KO-2 cells at a multiplicity of infection of 0.01. 615 
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Virus titers were determined by plaque assay in normal HmLu-1 cells. The data 616 
are reported as the mean titer of three clones of each KO cell (EXT2KO-1, 617 
EXT2KO-2, or random-KO) with standard deviations. (C) Infectivities of AKAV 618 
and SBV in HSPG-KO cells. Random-KO or HSPG-KO cells were infected with 619 
AKAV(OBE-1), AKAV(Iriki), SBV, or control VSV-ΔG-GFP. Cells were stained for 620 
AKAV or SBV antigen, and positive cells were counted under a fluorescent 621 
microscope. For VSV-ΔG-GFP-infected cells, GFP-positive cells were counted 622 
under a fluorescent microscope. Results are expressed as percentages relative 623 
to the number of positive random-KO cells. The data are reported as the mean 624 
value of three clones of each KO cell (EXT2KO-1, EXT2KO-2, or Random-KO) 625 
with standard deviations. (D) Infectivities of VSV pseudotyped with AKAV Gn/Gc 626 
(VSV-ΔG-GFP/AKAV) in HSPG-KO cells. Random-KO or HSPG-KO cells were 627 
infected with VSV-ΔG-GFP/AKAV or control VSV-ΔG-GFP. GFP-positive cells 628 
were counted under a fluorescent microscope. Results are represented as 629 
percentages relative to the number of positive random-KO cells. The data are 630 
shown as the mean value of three clones of each KO cell (EXT2KO-1, 631 
EXT2KO-2 or random-KO) with standard deviations. 632 
 633 
 634 
Fig. 3. AKAV and SBV binding assays in HSPG-KO cells. (A) Real-time reverse 635 
transcription-polymerase chain reaction (RT-PCR) for the quantification of cell 636 
surface-attached viruses. AKAV(OBE-1) or SBV was incubated with HSPG-KO 637 
cells at 4°C. After a washing step, total RNAs were extracted. AKAV or SBV S 638 
RNAs were quantified by one-step real-time RT-PCR. For relative quantification, 639 
26 
 
standard curves of AKAV or SBV S RNA and GAPDH were prepared by serial 640 
dilution of a mixture of total RNA from uninfected HmLu-1 cells and RNA 641 
extracted from AKAV(OBE-1) or SBV-containing supernatants. Results are 642 
expressed as the percentages relative to the levels in random-KO cells. The 643 
results are representative of three different experiments. (B) Sandwich ELISA for 644 
the detection of N proteins of AKAV attached to cell surfaces. AKAV(OBE-1) was 645 
inoculated onto HSPG-KO or random-KO HmLu-1 cells for 1 h at 4°C. After a 646 
washing step, the cells were lysed, and the lysates were added to the anti-AKAV 647 
N monoclonal antibody (5E8)-coated wells of 96-well ELISA plates (Maxisorp, 648 
Nunc), followed by incubation with biotinylated anti-AKAV mouse polyclonal 649 
antibody. Subsequently, the wells were incubated with avidin-biotinylated 650 
horseradish peroxidase (HRP) complex (VECTASTAIN ABC Kit, Vector 651 
Laboratories). A 3,3′,5,5′-tetramethylbenzidine (TMB) substrate solution was 652 
used for detection, and optical density values were measured. Results are 653 
expressed as percentages relative to the number of positive random-KO cells. 654 
The results are representative of three independent experiments. 655 
 656 
Fig. 4. Rescue of AKAV and SBV infectivities by add-back of the EXT2 gene in 657 
EXT2-KO cells. (A) Flow cytometric analysis of adding back the EXT2 gene in 658 
EXT2KO-1 HmLu-1 cells. Cells were labeled with anti-heparan sulfate 659 
mouse-monoclonal antibody (10E4) and analyzed by flow cytometry (FACS 660 
verse, BD Biosciences). (B) Infectivities of AKAV and SBV in EXT2-added back 661 
cells. The cells were infected with AKAV(OBE-1), AKAV(Iriki), or SBV. Cells were 662 
stained for AKAV or SBV antigen, and positive cells were counted under a 663 
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fluorescent microscope. Results are expressed as percentages relative to the 664 
number of wild-type cells. The data are reported as the mean value with 665 
standard deviations for three independent experiments. 666 
AKAV(OBE-1)
AKAV(Iriki)
SBV
0
20
40
60
80
100
120
0 125 250 375 500 625 750 875 1000
P
la
q
u
e
 f
o
rm
a
ti
o
n
 in
h
ib
it
io
n
 (
%
)
Heparin (µg/mL)
AKAV(Iriki)
SBV
AKAV(OBE-1)
A B
VSV-ΔG-GFP
0
20
40
60
80
100
120
R
e
la
ti
v
e
 i
n
fe
c
ti
v
it
y
 (
%
)
0 20 78 313 1250 5000
Heparinase (µU/µL)
01
2
3
4
5
6
7
8
9
0 12 24 36 48
0
1
2
3
4
5
6
7
8
0 12 24 36 48
0
1
2
3
4
5
6
7
8
9
0 12 24 36 48
Time post-infection (h) Time post-infection (h) Time post-infection (h)
In
fe
c
ti
v
it
y
 t
it
e
r 
(P
F
U
/m
L
)
In
fe
c
ti
v
it
y
 t
it
e
r 
(P
F
U
/m
L
)
In
fe
c
ti
v
it
y
 t
it
e
r 
(P
F
U
/m
L
)
Random-KO Random-KO Random-KOEXT2KO-1
EXT2KO-1
EXT2KO-1
EXT2KO-2
EXT2KO-2
EXT2KO-2
AKAV(OBE-1) AKAV(Iriki) SBV
100
200
500
400
300
100
200
500
400
300
600
700
100
200
500
400
300
100
200
500
400
300
600
700
900
800
0 102 105104103 0 102 105104103 0 102 105104103 0 102 105104103
C
o
u
n
t
C
o
u
n
t
C
o
u
n
t
C
o
u
n
t
Wild-type Random-KO EXT2KO-1 EXT2KO-2
HSPG (Alexa488) HSPG (Alexa488) HSPG (Alexa488) HSPG (Alexa488)
A
B
0
20
40
60
80
100
120
0
20
40
60
80
100
120
0
20
40
60
80
100
120140
E
X
T2
K
O
-1
E
X
T2
K
O
-2
R
an
do
m
-K
O
In
fe
c
ti
o
n
 (
%
 t
o
 R
a
n
d
o
m
-K
O
)
In
fe
c
ti
o
n
 (
%
 t
o
 R
a
n
d
o
m
-K
O
)
In
fe
c
ti
o
n
 (
%
 t
o
 R
a
n
d
o
m
-K
O
)
AKAV(OBE-1) AKAV(Iriki) SBV
C
VSV-ΔG-GFP
0
20
40
60
80
100
120
In
fe
c
ti
o
n
 (
%
 t
o
 R
a
n
d
o
m
-K
O
)
E
X
T2
K
O
-1
E
X
T2
K
O
-2
R
an
do
m
-K
O
E
X
T2
K
O
-1
E
X
T2
K
O
-2
R
an
do
m
-K
O
E
X
T2
K
O
-1
E
X
T2
K
O
-2
R
an
do
m
-K
O
140
D
E
X
T2
K
O
-1
E
X
T2
K
O
-2
R
an
do
m
-K
O
E
X
T2
K
O
-1
E
X
T2
K
O
-2
R
an
do
m
-K
O
0
20
40
60
80
100
120
In
fe
c
ti
o
n
 (
%
 t
o
 R
a
n
d
o
m
-K
O
)
0
20
40
60
80
100
120
In
fe
c
ti
o
n
 (
%
 t
o
 R
a
n
d
o
m
-K
O
)
VSV-ΔG-GFP/AKAV VSV-ΔG-GFP
020
40
60
80
100
120
0
20
40
60
80
100
120
0
20
40
60
80
100
120
AKAV(OBE-1) SBV
O
D
 (
%
 t
o
 R
a
n
d
o
m
-K
O
)
R
e
la
ti
v
e
 c
o
p
y
 n
u
m
b
e
r
 (
%
 t
o
 R
a
n
d
o
m
-K
O
)
R
e
la
ti
v
e
 c
o
p
y
 n
u
m
b
e
r
 (
%
 t
o
 R
a
n
d
o
m
-K
O
)
A B
E
X
T2
K
O
-1
E
X
T2
K
O
-2
R
an
do
m
-K
O
E
X
T2
K
O
-1
E
X
T2
K
O
-2
R
an
do
m
-K
O
E
X
T2
K
O
-1
E
X
T2
K
O
-2
R
an
do
m
-K
O
020
40
60
80
100
120
140
160
180
WT EXT2KO Add-back
AKAV(OBE-1)
0
20
40
60
80
100
120
140
WT EXT2KO Add-back
AKAV(Iriki)
0
20
40
60
80
100
120
WT EXT2KO Add-back
SBV
100
200
50
400
300
150
C
o
u
n
t
0 102 105104103
HSPG (Alexa488)
0 102 105104103
HSPG (Alexa488)
0 102 105104103
HSPG (Alexa488)
100
200
400
300
250
350
450
100
200
50
400
300
150
250
350
450
0 00
500
C
o
u
n
t
C
o
u
n
t
Wild-type EXT2KO-1 EXT2 add-back
In
fe
c
ti
v
it
y
 (
%
 t
o
 W
T
)
In
fe
c
ti
v
it
y
 (
%
 t
o
 W
T
)
In
fe
c
ti
v
it
y
 (
%
 t
o
 W
T
)
A
B
